NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.
NeuroDerm Announces Issuance of a New U.S. Patent for Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions
ND0701’s formulation, containing concentrated apomorphine-base, is intended for chronic therapy of Parkinson’s disease and is developed for continuous subcutaneous administration by a small, low-volume, disposable patch-pump.”> Read More
NeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson’s Disease
ND0701 complements the company’s product pipeline for the treatment of advanced Parkinson’s disease ”> Read More